qpx7831
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 13, 2021 (NCT04578873)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- ADC-11INHIBITOR
ampC inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06157242 | Phase 1 | Jun 1, 2024 | Department of Health and Human Services, Qpex Biopharma, Inc., Shionogi |
| NCT06079775 | Phase 1 | Jan 20, 2024 | Department of Health and Human Services, Qpex Biopharma, Inc., Shionogi |
| NCT04578873 | Phase 1 | Apr 13, 2021 | Department of Health and Human Services, Qpex Biopharma, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Health and Human Services | Government | 3 | 0 | 1 | 2021 |
| Qpex Biopharma, Inc. | For profit | 3 | 3 | 1 | 2021 |
| Shionogi | For profit | 2 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1